相关实验视频
Updated: Jul 8, 2025

11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.3K
由Gi/Gs蛋白竞争介导的大麻素CB1受体的定量药理模型
Liang Yang1, David B Finlay2, Hayley M Green2
1Otago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin, New Zealand.
British journal of pharmacology
|December 10, 2023
概括
一个数学模型表明,G蛋白预合解释了CB1受体信号切换如何从抑制到刺激cAMP生产. 这一发现指导了未来对CB1受体 (大麻素受体1) 功能的实验.
科学领域:
- 分子药理学分子药理学
- 计算生物学是一种计算生物学.
- 细胞信号传递 细胞信号传递
背景情况:
- 大麻素受体1 (CB1) 激活通常通过Gi信号来抑制cAMP的产生.
- 矛盾的是,CB1对cAMP的刺激与D2受体的共同刺激或高表达一起发生.
- 两个假设涉及Gi消耗或信号交换机的受体二元化.
研究的目的:
- 探索Gi/Gs在CB1受体激活中的信号偏好机制.
- 使用数学模型研究G蛋白预合和受体二元化的作用.
- 要区分关于CB1介导的cAMP刺激的拟议假设.
主要方法:
- 开发CB1受体信号通路的数学模型.
- 模型校准使用cAMP生产,Gi解离和受体内部化数据.
- 模拟分析以检查提出假设的关键步骤.
- 设计实验以区分相互竞争的假设.
主要成果:
- 数学模型成功地描述了假设1下的实验数据.
- 模拟显示,G蛋白预合对于观察到的信号交换机至关重要.
- 对于旨在区分假设的实验,预测了不同的cAMP反应.
结论:
- 为CB1受体调节的Gi/Gs通路建立了一个可行的数学模型.
- G蛋白预合被确定为切换CB1信号到cAMP刺激的关键因素.
- 模型衍生实验设计为未来研究CB1受体信号机制提供指导.
相关概念视频
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Quantitative Aspects of Drug-Receptor Interaction
999
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
999
Drug-Receptor Interactions
5.2K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.2K
GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
IP3/DAG Signaling Pathway
12.1K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.1K
Transducer Mechanism: G Protein–Coupled Receptors
2.0K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.0K

